Canada-based ZYUS Life Sciences Corporation (TSXV:ZYUS), a clinical-stage life sciences company focused on the development and commercialisation of novel non-opioid drug candidates for pain management, announced on Tuesday that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,616,704, entitled 'Cannabichromene formulation for pain management'.

Held by ZYUS's wholly owned subsidiary, ZYUS Life Sciences Inc, the new US patent is based on International Patent Application No. PCT/CA2021/050430 and covers a novel, non-intoxicating approach to pain management.

This represents the company's second US patent in pain management. ZYUS's first US patent supports its lead drug candidate, Trichomylin softgel capsules, a proprietary fixed-dose combination for pain management by delivering a balanced ratio of cannabinoids, which includes cannabichromene (CBC).

The company says that the newly issued patent relates to its second drug candidate, further expanding its pipeline of novel, proprietary, non-opioid therapies and supports ongoing clinical research targeting neuropathic pain, including peripheral neuropathy, such as diabetic and cancer-related neuropathies.

ZYUS's latest US patent further strengthens the continued development of its second drug candidate, for which Investigational New Drug (IND)-enabling studies have been completed to support the potential initiation of clinical trials in the United States. The patent provides additional intellectual property protection alongside potential regulatory exclusivity for CBC, whether as monotherapy or within its lead drug product, Trichomylin softgel capsules, subject to regulatory determination by the US Food and Drug Administration (FDA) at the time of marketing authorisation.